Squamous Cell Carcinoma Clinical Trial
Official title:
Phase III Study Of Post-Operative Adjuvant Concurrent Chemoradiotherapy For High Risk Oral Cavity Squamous Cell Carcinoma Patients
The purpose of this study is to confirm the value of concurrent chemoradiotherapy in improving the locoregional control and survival of patients with resected locally advanced HNSCC, a phase III randomized study is proposed. The population studied in this trial is limited to patients of oral cavity cancer; this could reduce the confounding factor of varying prognosis in patients of different primary sites of HNSCC.
Potentially resectable Stage III or IV squamous cell carcinomas of the head and neck (HNSCC)
are treated by operation and adjuvant radiotherapy. The 5-year survival rate is
approximating 30%. Recurrence typically occurs within 3 years, 60-80% in locoregional sites,
and 20-30% systemically. Patients who are found to have tumors at the margins of surgical
specimens far particularly poorly.
Chemotherapy has been added in the hope to improve this situation. Induction and adjuvant
chemotherapy has resulted in a decrease in the appearance of systemic metastases in most
trials, but has not improved locoregional control and survival.
For cases with unresectable head and neck cancers, concurrent chemoradiotherapy appears to
have improved locoregional control, disease-free survival, and possibly overall survival, as
compared to radiotherapy alone. Bachaud et al. reported a randomized trial of postoperative
cisplatin and radiotherapy vs. radiotherapy alone for patients with Stage III or IV head and
neck cancer. Cisplatin was administered 50 mg weekly during radiotherapy. There was a
significant improvement in locoregional control (70% vs. 55%) as well as overall survival
(median 36m vs. 20m) in patients who received concurrent chemoradiotherapy. Al-Sarraf et al.
also reported a phase II concurrent chemoradiotherapy trial, using cisplatin 100 mg/m2 every
three weeks. Based on comparison with similar patients treated in a prior RTOG trial, they
conclude that postoperative radiotherapy with concurrent cisplatin may improve locoregional
control rates10. The superiority of adjuvant concurrent chemoradiotherapy (CCRT) to RT alone
or sequential adjuvant RT and chemotherapy has been further confirmed in an analysis of data
of RTOG 85-03 and RTOG 88-24. Comparing high-risk patients of RTOG 85-03 with prognostically
similar patients from RTOG 88-24, the data suggest that sequential surgery, RT, and
chemotherapy produced better locoregional control than surgery plus RT, but that surgery
followed by CCRT produced even higher locoregional control. Independent of the differences
in the amount of RT delivered, the Cox proportional hazards model suggests that the addition
of CCRT resulted in a 50% decrease in locoregional relapse rates compared with surgery plus
postoperative RT with no chemotherapy. The reduction in mortality was 18%.
Although CCRT may be better than RT alone or sequential treatment, the 3 year survival in
both adjuvant CCRT studies were only around 50%. Is more aggressive treatment warranted?
Tolerance to CCRT is a major concern. In the French study, severe acute toxicity occurred in
18% of RT only patients and 41% of patients received CCRT. In the RTOG 88-24 trial, severe
and life-threatening toxicities occurred in 20% and 12% of patients, respectively; the most
common drug-related toxicities were leukopenia, anemia, nausea, and vomiting .
Theoretically, to optimize CCRT, continuous presence of chemotherapeutic drug or drug effect
is necessary to maximize the effect of radiosensitization. For radiosensitization purpose,
daily chemotherapy may be better than weekly and weekly may be better than tri-weekly.
French study used weekly cisplatin with a dose of 30 mg/m2. RTOG 88-24 used different
treatment dose and schedule 100 mg/m2 of cisplatin on radiotherapy days 1, 23 and 43. We
choose weekly for convenience and hope this can increase the recruitment of patients. In the
pilot study, we observed a remarkable toxicity with this treatment schedule. Considering the
remarkable toxicity reported and our preliminary experience, more drugs, higher dosage, or
extended schedule may not be justified.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02213133 -
Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas
|
Phase 2 | |
Not yet recruiting |
NCT04533321 -
A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell Carcinoma
|
Phase 2 | |
Terminated |
NCT02890368 -
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
|
Phase 1 | |
Active, not recruiting |
NCT01232374 -
Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
Withdrawn |
NCT01148082 -
School Response to Families Who Have Children With Cancer
|
N/A | |
Completed |
NCT01208883 -
A Feasibility Study On Continuous Adaptive [18f]Fdg-Pet-Guided Radiotherapy For Head and Neck Cancer
|
Phase 1 | |
Completed |
NCT01089803 -
Observational Study of Swallowing Function After Treatment of Advanced Laryngeal Cancer
|
N/A | |
Terminated |
NCT00707655 -
Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy
|
Phase 1/Phase 2 | |
Completed |
NCT00586040 -
Photochemical Tissue Bonding
|
Phase 2 | |
Completed |
NCT01127737 -
Warning Signs of Squamous Cell Carcinoma and Prevention of SCC by at Risk Organ Transplant Recipients
|
N/A | |
Completed |
NCT00793169 -
Serum Concentration of Lidocaine After Local Injection During Mohs Micrographic Surgery
|
||
Completed |
NCT00409565 -
A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer
|
Phase 2 | |
Completed |
NCT00176267 -
Paclitaxel, Carboplatin And Low Dose Radiation As Induction Therapy In Locally Advanced Head And Neck Cancer
|
Phase 2 | |
Terminated |
NCT04685798 -
Optimized Diffusion-Weighted Imaging for the Evaluation of Post-Treatment Squamous Cell Carcinoma in the Neck: Comparative Study With FDG PET/CT
|
N/A | |
Recruiting |
NCT04370587 -
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04475952 -
Early Diagnosis of Upper Digestive Tract Disease
|
||
Recruiting |
NCT04435938 -
A Study of SBRT for Squamous Cell Carcinoma of the Head and Neck
|
Phase 2 | |
Not yet recruiting |
NCT05852665 -
Buccal Cancer Resection Ultrasound Guided
|
N/A | |
Recruiting |
NCT05048459 -
Comparing Two Surveillance Approaches for People Who Have Received Treatment for HPV-associated Head and Neck Cancer and Show No Signs of Disease
|
N/A | |
Suspended |
NCT03952585 -
De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
|
Phase 2/Phase 3 |